CA2164155C - Vaccin a base de polysaccharide permettant d'ameliorer l'immunite contre la brucellose - Google Patents

Vaccin a base de polysaccharide permettant d'ameliorer l'immunite contre la brucellose Download PDF

Info

Publication number: CA2164155C
Authority: CA; Canada
Prior art keywords: brucella; vaccine; ops; polysaccharide; abortus
Prior art date: 1995-11-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2164155

Other languages

English (en)

Other versions

CA2164155A1 (fr

Inventor

John W. Cherwonogrodzky

Jonathan P. Wong

Vincent L. Dininno

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Minister of National Defence of Canada

Original Assignee

Minister of National Defence of Canada

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-30

Filing date

1995-11-30

Publication date

2005-06-21

1995-11-30 Application filed by Minister of National Defence of Canada filed Critical Minister of National Defence of Canada

1995-11-30 Priority to CA 2164155 priority Critical patent/CA2164155C/fr

1996-09-16 Priority to US08/672,063 priority patent/US5951987A/en

1997-05-31 Publication of CA2164155A1 publication Critical patent/CA2164155A1/fr

2005-06-21 Application granted granted Critical

2005-06-21 Publication of CA2164155C publication Critical patent/CA2164155C/fr

2015-11-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

206010006500 Brucellosis Diseases 0.000 title claims abstract description 31
230000036039 immunity Effects 0.000 title description 7
229940031937 polysaccharide vaccine Drugs 0.000 title description 5
229960005486 vaccine Drugs 0.000 claims abstract description 69
241000589562 Brucella Species 0.000 claims abstract description 30
230000004224 protection Effects 0.000 claims abstract description 30
208000015181 infectious disease Diseases 0.000 claims abstract description 25
241000894006 Bacteria Species 0.000 claims abstract description 21
229920001282 polysaccharide Polymers 0.000 claims abstract description 20
239000005017 polysaccharide Substances 0.000 claims abstract description 20
241000589567 Brucella abortus Species 0.000 claims description 38
102000036639 antigens Human genes 0.000 claims description 23
108091007433 antigens Proteins 0.000 claims description 23
239000000427 antigen Substances 0.000 claims description 22
229940056450 brucella abortus Drugs 0.000 claims description 16
241001148111 Brucella suis Species 0.000 claims description 14
241000607142 Salmonella Species 0.000 claims description 10
241000607447 Yersinia enterocolitica Species 0.000 claims description 7
229940098232 yersinia enterocolitica Drugs 0.000 claims description 7
241000588732 Atlantibacter hermannii Species 0.000 claims description 5
241001148106 Brucella melitensis Species 0.000 claims description 5
241000588724 Escherichia coli Species 0.000 claims description 5
241000589602 Francisella tularensis Species 0.000 claims description 5
241000122973 Stenotrophomonas maltophilia Species 0.000 claims description 5
229940038698 brucella melitensis Drugs 0.000 claims description 5
229940118764 francisella tularensis Drugs 0.000 claims description 5
241000607626 Vibrio cholerae Species 0.000 claims description 4
230000002480 immunoprotective effect Effects 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
231100000252 nontoxic Toxicity 0.000 claims description 4
230000003000 nontoxic effect Effects 0.000 claims description 4
230000004936 stimulating effect Effects 0.000 claims description 4
229940118696 vibrio cholerae Drugs 0.000 claims description 4
230000024932 T cell mediated immunity Effects 0.000 claims description 2
241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims 2
241000124008 Mammalia Species 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
244000005700 microbiome Species 0.000 claims 1
230000002458 infectious effect Effects 0.000 abstract description 6
239000002158 endotoxin Substances 0.000 description 31
229920006008 lipopolysaccharide Polymers 0.000 description 31
241000699670 Mus sp. Species 0.000 description 26
238000002347 injection Methods 0.000 description 17
239000007924 injection Substances 0.000 description 17
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
210000004027 cell Anatomy 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
241000282898 Sus scrofa Species 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
210000000952 spleen Anatomy 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
230000001681 protective effect Effects 0.000 description 9
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
241000283690 Bos taurus Species 0.000 description 7
UEHGPSGGFKLPTD-KVTDHHQDSA-N perosamine Chemical compound C[C@@H](O)[C@@H](N)[C@H](O)[C@H](O)C=O UEHGPSGGFKLPTD-KVTDHHQDSA-N 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000002502 liposome Substances 0.000 description 6
238000000034 method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241001133525 Brucella abortus 2308 Species 0.000 description 5
241000700198 Cavia Species 0.000 description 5
150000004676 glycans Chemical class 0.000 description 5
230000004044 response Effects 0.000 description 5
206010000210 abortion Diseases 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
239000002054 inoculum Substances 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
229920001817 Agar Polymers 0.000 description 3
241000009259 Brucella abortus S19 Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
231100000176 abortion Toxicity 0.000 description 3
239000008272 agar Substances 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
230000008348 humoral response Effects 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000011160 research Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
CVBNMWXECPZOLM-UHFFFAOYSA-N Rhamnetin Natural products COc1cc(O)c2C(=O)C(=C(Oc2c1)c3ccc(O)c(O)c3O)O CVBNMWXECPZOLM-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
241000282887 Suidae Species 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
229910001873 dinitrogen Inorganic materials 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
244000144972 livestock Species 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
229940125575 vaccine candidate Drugs 0.000 description 2
238000004383 yellowing Methods 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000157302 Bison bison athabascae Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006495 Brucella infections Diseases 0.000 description 1
241000792667 Brucella melitensis B115 Species 0.000 description 1
101100279438 Caenorhabditis elegans egg-3 gene Proteins 0.000 description 1
241000282421 Canidae Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
241001125840 Coryphaenidae Species 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
241001646719 Escherichia coli O157:H7 Species 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
229920001503 Glucan Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
LKDRXBCSQODPBY-NSHGFSBMSA-N L-fructose Chemical compound OCC1(O)OC[C@H](O)[C@H](O)[C@H]1O LKDRXBCSQODPBY-NSHGFSBMSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002359 Tetronic® Polymers 0.000 description 1
241000775914 Valdivia <angiosperm> Species 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
SHZGCJCMOBCMKK-PQMKYFCFSA-N alpha-D-rhamnose Chemical compound C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
231100000319 bleeding Toxicity 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000004891 communication Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
BABWHSBPEIVBBZ-UHFFFAOYSA-N diazete Chemical compound C1=CN=N1 BABWHSBPEIVBBZ-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000010408 film Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000009027 insemination Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
PIQIFFQSDJDXOS-DBRKOABJSA-N n-[(2r,3r,4s,5s)-2,4,5-trihydroxy-6-oxohexan-3-yl]formamide Chemical compound O=CN[C@H]([C@H](O)C)[C@H](O)[C@H](O)C=O PIQIFFQSDJDXOS-DBRKOABJSA-N 0.000 description 1
230000004719 natural immunity Effects 0.000 description 1
206010029410 night sweats Diseases 0.000 description 1
230000036565 night sweats Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
238000007747 plating Methods 0.000 description 1
201000006509 pleuropneumonia Diseases 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000009418 renovation Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000009589 serological test Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
230000009295 sperm incapacitation Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000010409 thin film Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/098—Brucella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

CA 2164155 1995-08-22 1995-11-30 Vaccin a base de polysaccharide permettant d'ameliorer l'immunite contre la brucellose Expired - Lifetime CA2164155C (fr)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
CA 2164155 CA2164155C (fr)	1995-11-30	1995-11-30	Vaccin a base de polysaccharide permettant d'ameliorer l'immunite contre la brucellose
US08/672,063 US5951987A (en)	1995-08-22	1996-09-16	Polysaccharide vaccine to enhance immunity against brucellosis

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2164155 CA2164155C (fr)	1995-11-30	1995-11-30	Vaccin a base de polysaccharide permettant d'ameliorer l'immunite contre la brucellose

Publications (2)

Publication Number	Publication Date
CA2164155A1 CA2164155A1 (fr)	1997-05-31
CA2164155C true CA2164155C (fr)	2005-06-21

Family

ID=4157067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2164155 Expired - Lifetime CA2164155C (fr)	1995-08-22	1995-11-30	Vaccin a base de polysaccharide permettant d'ameliorer l'immunite contre la brucellose

Country Status (1)

Country	Link
CA (1)	CA2164155C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6444210B1 (en)	1996-07-03	2002-09-03	Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence of Her Majesty′s Canadian Goverment	Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity

1995
- 1995-11-30 CA CA 2164155 patent/CA2164155C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2164155A1 (fr)	1997-05-31

Legal Events

Date	Code	Title	Description
1998-02-23	EEER	Examination request
2016-02-01	MKEX	Expiry	Effective date: 20151130

Publication	Publication Date	Title
JP2640525B2 (ja)	1997-08-13	無毒の微生物とその使用
US8669355B2 (en)	2014-03-11	Vaccine
Esteve-Gassent et al.	2004	Efficacy of a bivalent vaccine against eel diseases caused by Vibrio vulnificus after its administration by four different routes
JP2004536106A (ja)	2004-12-02	マイコプラズマ・ボビスワクチンおよび動物の肺炎を減少させる方法
TW557214B (en)	2003-10-11	Attenuated live Neospora vaccine
JPH0811735B2 (ja)	1996-02-07	抗原性遺伝子ワクチン
Fouz et al.	2001	Field testing of a vaccine against eel diseases caused by Vibrio vulnificus
CA1336406C (fr)	1995-07-25	Composition de vaccin pour bovins et methode pour la prevention de l'infection par les trichomas a l'aide de celle-ci
KR20030036647A (ko)	2003-05-09	마이코플라스마 하이오뉴모니에에 대한 온도-감수성 생 백신
Ahangarzadeh et al.	2023	Effect of killed autogenous polyvalent vaccines against Vibrio harveyi, V. alginolyticus and Streptococcus iniae on survival and immunogenicity of Asian seabass (Lates calcarifer)
Parmley et al.	2002	Protective effects of immunization with a recombinant cyst antigen in mouse models of infection with Toxoplasma gondii tissue cysts
US5951987A (en)	1999-09-14	Polysaccharide vaccine to enhance immunity against brucellosis
Villarreal et al.	1992	Proliferative and T-cell specific interleukin (IL-2/IL-4) production responses in spleen cells from mice vaccinated with aroA live attenuated Salmonella vaccines
Chakrabarti et al.	1999	Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis
US7442374B2 (en)	2008-10-28	Composition for increasing the survival to slaughter rate of piglets
CA2164155C (fr)	2005-06-21	Vaccin a base de polysaccharide permettant d'ameliorer l'immunite contre la brucellose
WO1993010815A1 (fr)	1993-06-10	Mutants non encapsules de bacteries utiles comme vaccins
US20020187162A1 (en)	2002-12-12	Use of a live attenuated Mycoplasma gallisepticum strain as a vaccine and vector for the protection of chickens and turkeys from respiratory disease
Marx	1980	Vaccinating with Bacterial Pili: Protection against a number of diseases, including gonorrhea, may be possible by immunizing with the bacterial surface components called pili
AU2018359019B2 (en)	2024-08-08	Vaccine
US6881412B1 (en)	2005-04-19	Modified live Flavobacterium columnare against columnaris disease in fish
US12005110B2 (en)	2024-06-11	Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae
Johnson et al.	1986	Intracerebral infection of mice with ovine strains of Chlamydia psittaci: an animal screening test for the assay of vaccines
Pier	2004	Vaccines and vaccination
Pascual	2020	Mucosal Approaches for Systemic Immunity to Anthrax, Brucellosis, and Plague